Defendant
3 cases as defendant.
Antitrust/purchaser-overcharge action against Celgene and Bristol Myers Squibb. The complaint references the '3939 patent and the method-of-treatment patent tree as part of the alleged monopolization scheme. Case is pending.
Antitrust/purchaser-overcharge action alleging monopolization of pomalidomide. The '3939 patent is cited in the complaint as part of the alleged scheme to delay generic entry. Motion to dismiss denied in part; proceeding.
CenterWell filed monopolization claims under Section 2 of the Sherman Act against Celgene and Bristol Myers Squibb, citing the '647/'648/'649 patents as part of an alleged pay-for-delay scheme.